XIENCE V Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study.

Trial Profile

XIENCE V Everolimus Eluting Coronary Stent System India Post-marketing Single-Arm Study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms XIENCE-V-India
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 24 Aug 2016 Last checked against Clinical Trials Registry - India.
    • 13 Aug 2012 Actual end date (Aug 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top